.Attribute Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of clients along with HER2+ enhanced bosom cancer cells and energetic or even dependable mind metastases presented constant intracranial task and also systemic efficiency of T-DXd.